Gepirone

Gepirone

Clinical data
Routes of administration	Oral
ATC code	N06AX19 (WHO)
Legal status
Legal status	In general: uncontrolled
Pharmacokinetic data
Elimination half-life	2-3 hours
Identifiers
IUPAC name 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
CAS Number	83928-76-1
PubChem CID	55191
ChemSpider	49836 Y
UNII	JW5Y7B8Z18
ChEMBL	ChEMBL284092 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H29N5O2
Molar mass	359.46586 g/mol
3D model (JSmol)	Interactive image
SMILES O=C1N(C(=O)CC(C)(C)C1)CCCCN3CCN(c2ncccn2)CC3
InChI InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3 Y Key:QOIGKGMMAGJZNZ-UHFFFAOYSA-N Y
(verify)

WikiDoc Resources for Gepirone
Articles
Most recent articles on Gepirone Most cited articles on Gepirone Review articles on Gepirone Articles on Gepirone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gepirone Images of Gepirone Photos of Gepirone Podcasts & MP3s on Gepirone Videos on Gepirone
Evidence Based Medicine
Cochrane Collaboration on Gepirone Bandolier on Gepirone TRIP on Gepirone
Clinical Trials
Ongoing Trials on Gepirone at Clinical Trials.gov Trial results on Gepirone Clinical Trials on Gepirone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gepirone NICE Guidance on Gepirone NHS PRODIGY Guidance FDA on Gepirone CDC on Gepirone
Books
Books on Gepirone
News
Gepirone in the news Be alerted to news on Gepirone News trends on Gepirone
Commentary
Blogs on Gepirone
Definitions
Definitions of Gepirone
Patient Resources / Community
Patient resources on Gepirone Discussion groups on Gepirone Patient Handouts on Gepirone Directions to Hospitals Treating Gepirone Risk calculators and risk factors for Gepirone
Healthcare Provider Resources
Symptoms of Gepirone Causes & Risk Factors for Gepirone Diagnostic studies for Gepirone Treatment of Gepirone
Continuing Medical Education (CME)
CME Programs on Gepirone
International
Gepirone en Espanol Gepirone en Francais
Business
Gepirone in the Marketplace Patents on Gepirone
Experimental / Informatics
List of terms related to Gepirone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is an antidepressant and anxiolytic of the azapirone class. Like other azapirones, it acts as a selective partial agonist of the 5-HT_1A receptor. Gepirone was under development in the U.S. in an extended release form, but despite completing phase III clinical trials, it failed to pass the drug approval process. As a result, gepirone, despite already having brand names picked out, did not manage to reach the pharmaceutical market.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. There have been no updates on gepirone since.

Synthesis

Ormaza, V. A.; 1986, ES 8606333 .